Surmodics FY2026 EPS Forecast Lifted by Barrington Research

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Analysts at Barrington Research increased their FY2026 earnings estimates for shares of Surmodics in a note issued to investors on Thursday, November 7th. Barrington Research analyst M. Petusky now forecasts that the company will post earnings of $0.89 per share for the year, up from their previous forecast of $0.87. The consensus estimate for Surmodics' current full-year earnings is $0.17 per share.

Other equities analysts have also issued research reports about the company. StockNews.com initiated coverage on Surmodics in a research note on Thursday. They issued a "hold" rating on the stock. Needham & Company LLC restated a "hold" rating on shares of Surmodics in a report on Thursday. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $50.00.

Surmodics Trading Up 0.1 %

SRDX traded up $0.02 during trading on Monday, reaching $38.48. 89,041 shares of the company's stock were exchanged, compared to its average volume of 230,178. The company's fifty day moving average price is $38.57 and its 200-day moving average price is $38.86. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.22 and a current ratio of 3.98. The firm has a market capitalization of $548.99 million, a PE ratio of -47.48 and a beta of 1.20. Surmodics has a fifty-two week low of $25.17 and a fifty-two week high of $42.44.

Surmodics (NASDAQ:SRDX - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.14. The company had revenue of $33.23 million during the quarter, compared to analysts' expectations of $30.69 million. Surmodics had a negative net margin of 9.15% and a negative return on equity of 3.77%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets lifted its stake in Surmodics by 7.5% in the 1st quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company's stock valued at $202,000 after acquiring an additional 481 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Surmodics by 14.7% in the first quarter. SG Americas Securities LLC now owns 5,138 shares of the company's stock worth $151,000 after purchasing an additional 660 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in Surmodics by 13.4% during the first quarter. Lazard Asset Management LLC now owns 5,679 shares of the company's stock worth $166,000 after purchasing an additional 673 shares during the last quarter. Quest Partners LLC grew its position in Surmodics by 107,100.0% in the third quarter. Quest Partners LLC now owns 1,072 shares of the company's stock valued at $42,000 after purchasing an additional 1,071 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its position in Surmodics by 3.5% in the second quarter. Los Angeles Capital Management LLC now owns 36,425 shares of the company's stock valued at $1,531,000 after purchasing an additional 1,221 shares in the last quarter. 96.63% of the stock is owned by institutional investors and hedge funds.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).